FY2029 EPS Estimates for Altimmune Cut by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – Research analysts at HC Wainwright cut their FY2029 earnings estimates for shares of Altimmune in a note issued to investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $1.26 per share for the year, down from their prior estimate of $1.30. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.

ALT has been the topic of several other research reports. UBS Group began coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, William Blair started coverage on Altimmune in a research note on Friday, February 28th. They set a “market perform” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Trading Down 2.3 %

Altimmune stock opened at $5.59 on Wednesday. The firm has a market capitalization of $430.51 million, a P/E ratio of -3.61 and a beta of 0.87. The business has a 50-day moving average of $6.70 and a 200-day moving average of $7.17. Altimmune has a 1 year low of $5.28 and a 1 year high of $11.50.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently added to or reduced their stakes in ALT. Larson Financial Group LLC bought a new position in shares of Altimmune during the 3rd quarter worth approximately $31,000. SBI Securities Co. Ltd. acquired a new position in Altimmune during the fourth quarter worth $45,000. Virtus ETF Advisers LLC bought a new position in Altimmune in the fourth quarter valued at $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune in the 4th quarter valued at $72,000. Finally, 180 Wealth Advisors LLC bought a new stake in Altimmune during the 4th quarter worth about $78,000. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.